首页> 外文期刊>Drug discovery today >Targeting endothelin receptors for pharmacotherapy of ischemic stroke: Current scenario and future perspectives
【24h】

Targeting endothelin receptors for pharmacotherapy of ischemic stroke: Current scenario and future perspectives

机译:靶向内皮素受体用于缺血性中风的药物治疗:当前情况和未来展望

获取原文
获取原文并翻译 | 示例
           

摘要

Increased expression of endothelin (ET) peptide and its receptors following ischemic stroke is found to regulate many critical aspects of stroke pathophysiology. Many attempts have been made to target ET receptors in various animal models of stroke, but it is very difficult to draw a definite line of conclusion, because these studies differ in many aspects, such as animal model, treatment schedule, parameters and techniques used for assessing these parameters. A meta-analysis of all studies showed a significant reduction in the lesion volume and improvement in functional outcome in focal cerebral ischemia. ET A receptor antagonists appear to offer an essential advantage of multiple neuroprotective mechanisms, including prevention of blood-brain barrier disruption and leukocyte infiltration.
机译:发现缺血性中风后内皮素(ET)肽及其受体的表达增加,可调节中风病理生理学的许多关键方面。在各种中风动物模型中已经进行了许多针对ET受体的尝试,但是很难得出明确的结论,因为这些研究在许多方面都有所不同,例如动物模型,治疗方案,用于治疗的参数和技术。评估这些参数。所有研究的荟萃分析显示,局灶性脑缺血病灶体积明显减少,功能结局改善。 ET A受体拮抗剂似乎提供了多种神经保护机制的基本优势,包括防止血脑屏障破坏和白细胞浸润。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号